A phase I study of the oral mTOR inhibitor ridaforolimus (RIDA) in combination with the IGF-1R antibody dalotozumab (DALO) in patients (pts) with advanced solid tumors.
Serena Di Cosimo(Fondazione IRCCS Istituto Nazionale dei Tumori), José Baselga(Harvard University), Ludmila Prudkin, Mark N. Stein(Cornell University), Desam Roda, J. C. Bendell, Andrés Cervantes(INCLIVA Health Research Institute), Yuqin Song(Peking University), Ann Leighton-Swayze, Scot Ebbinghaus(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 67
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
|New England Journal of Medicine|2013|3.4k